A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how much of the study drug, evacetrapib, enters the
blood stream and how long it takes the body to dispose of the study drug when given to
participants with severe renal (kidney) impairment compared to participants with normal renal
(kidney) function. This study will last approximately 8 weeks.